Determinants of poor adherence to secondary antibiotic prophylaxis for rheumatic fever recurrence on Lifou, New Caledonia: a retrospective cohort study

BMC Public Health

Eric D’Ortenzio³  Isabelle De Frémicourt²  Jean-Michel Meunier⁴  Bernard Rouchon¹  Noémie Baroux³  Brunelle Gasse³ 

[1] Agence Sanitaire et Sociale de la Nouvelle-Calédonie, Cellule du Rhumatisme Articulaire Aigu, Nouméa, Nouvelle-Calédonie;Direction de l’Action Communautaire et de l’Action Sanitaire de la Province des Iles, Nouméa, Nouvelle-Calédonie;Institut Pasteur de Nouvelle-Calédonie, Réseau International des Instituts Pasteur, Unité d’Epidémiologie des Maladies Infectieuses, Nouméa, Nouvelle-Calédonie;Cabinet de Cardiologie, Nouméa, Nouvelle-Calédonie

关键词: New Caledonia;    Melanesia;    Antibiotic prophylaxis;    Patient compliance;    Rheumatic heart disease;    Acute rheumatic fever;   

Others  :  1162548
DOI  :  10.1186/1471-2458-13-131

 received in 2012-09-19, accepted in 2013-02-08,  发布年份 2013

【 摘 要 】

Background

Incidence of acute rheumatic fever (ARF) and prevalence of rheumatic heart disease (RHD) in the Pacific region, including New Caledonia, are amongst the highest in the world. The main priority of long-term management of ARF or RHD is to ensure secondary prophylaxis is adhered to. The objectives of this study were to evaluate rates of adherence in people receiving antibiotic prophylaxis by intramuscular injections of penicillin in Lifou and to determine the factors associated with a poor adherence in this population.

Methods

We conducted a retrospective cohort study and we included 70 patients receiving injections of antibiotic prophylaxis to prevent ARF recurrence on the island of Lifou. Patients were classified as “good-adherent” when the rate of adherence was ≥80% of the expected injections and as “poor-adherent” when it was <80%. Statistical analysis to identify factors associated with adherence was performed using a multivariate logistic regression model.

Results

Our study showed that 46% of patients from Lifou receiving antibiotic prophylaxis for ARF or RHD had a rate of adherence <80% and were therefore at high risk of recurrence of ARF. Three independent factors were protective against poor adherence: a household with more than five people (odds ratio, 0.25; 95% confidence interval [CI], 0.08 to 0.75), a previous medical history of symptomatic ARF (odds ratio, 0.20; 95% CI, 0.04 to 0.98) and an adequate healthcare coverage (odds ratio, 0.21; 95% CI 0.06 to 0.72).

Conclusions

To improve adherence to secondary prophylaxis in Lifou, we therefore propose the following recommendations arising from the results of this study: i) identifying patients receiving antibiotic prophylaxis without medical history of ARF to strengthen their therapeutic education and ii) improving the medical coverage in patients with ARF or RHD. We also recommend that the nurse designated for the ARF prevention program in Lifou coordinate an active recall system based on an updated local register. But the key point to improve adherence among Melanesian patients is probably to give appropriate information regarding the disease and the treatment, taking into account the Melanesian perceptions of the disease.

【 授权许可】

   
2013 Gasse et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Marijon E, Mirabel M, Celermajer DS, Jouven X: Rheumatic heart disease. Lancet 2012, 379:953-964.
• [2]Steer AC, Carapetis JR, Nolan TM, Shann F: Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health 2002, 38:229-234.
• [3]World health organisation: WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986–90). Bull World Health Organ 1992, 70:213-218.
• [4]WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease: Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation, Geneva, 29 October - 1 November, 2001). Geneva Switzerland; 2001. 2004
• [5]McDonald M, Brown A, Noonan S, Carapetis JR: Preventing recurrent rheumatic fever: the role of register based programmes. Heart 2005, 91:1131-1133.
• [6]World Heart Federation: Diagnosis and Management of Acute Rheumatic Fever Rheumatic Heart Disease. Geneva: World Heart Federation before; 2007. updated in 2008
• [7]Manyemba J, Mayosi BM: Intramuscular penicillin is more effective than oral penicillin in secondary prevention of rheumatic fever–a systematic review. S Afr Med J 2003, 93:212-218.
• [8]Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA: Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009, 119:1541-1551.
• [9]RHD Australia (ARF/RHD writing group) National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 2nd edition. RHDAustralia: Menzies School of Health Research; 2012.
• [10]Steer AC, Colquhoun S, Kado J, Carapetis JR: Secondary prophylaxis is important for the prevention of recurrent rheumatic fever in the Pacific. Pediatr Cardiol 2011, 32:864-865.
• [11]Manyemba J, Mayosi BM: Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 2002, CD002227.
• [12]Steer AC, Carapetis JR: Prevention and treatment of rheumatic heart disease in the developing world. Nat Rev Cardiol 2009, 6:689-698.
• [13]Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, CD000011.
• [14]Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353:487-497.
• [15]World Health Organisation: Adherence to long-term therapies. Evidence for action. Geneva, Switzerland: World Health Organization; 2003.
• [16]Kumar R, Thakur JS, Aggarwal A, Ganguly NK: Compliance of secondary prophylaxis for controlling rheumatic fever and rheumatic heart disease in a rural area of northern India. Ind Heart J 1997, 49(3):283-288.
• [17]Bassili A, Zaher SR, Zaki A, Abdel-Fattah M, Tognoni G: Profile of secondary prophylaxis among children with rheumatic heart disease in Alexandria, Egypt. East Mediterr Health J 2000, 6:437-446.
• [18]Stewart T, McDonald R, Currie B: Acute rheumatic fever: adherence to secondary prophylaxis and follow up of Indigenous patients in the Katherine region of the Northern Territory. Aust J Rural Health 2007, 15:234-240.
• [19]Mincham CM, Mak DB, Plant AJ: The quality of management of rheumatic fever/ heart disease in the Kimberley. Aust N Z J Public Health 2002, 26:417-420.
• [20]Pelajo CF, Lopez-Benitez JM, Torres JM, de Oliveira SK: Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever. Pediatr Rheumatol Online J 2010, 8:22. BioMed Central Full Text
• [21]Eissa S, Lee R, Binns P, Garstone G, McDonald M: Assessment of a register-based rheumatic heart disease secondary prevention program in an Australian Aboriginal community. Aust N Z J Public Health 2005, 29:521-525.
• [22]Colquhoun SM, Carapetis JR, Kado JH, Steer AC: Rheumatic heart disease and its control in the Pacific. Expert Rev Cardiovasc Ther 2009, 7:1517-1524.
• [23]Baroux N, Rouchon B, Huon B, Germain A, Meunier JM, D'Ortenzio E: High prevalence of rheumatic heart disease in schoolchildren detected by echocardiography screening in New Caledonia. J Paediatr Child Health 2013.
• [24]WHO: Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
• [25]Seckeler MD, Hoke TR, Gurka MJ, Barton LL: No demonstrable effect of benzathine penicillin on recurrence of rheumatic Fever in pacific island population. Pediatr Cardiol 2010, 31:849-852.
• [26]Ehmke DA, Stehbens JA, Young L: Two studies of compliance with daily prophylaxis in rheumatic fever patients in Iowa. Am J Public Health 1980, 70:1189-1193.
• [27]Gordis L, Markowitz M, Lilienfeld AM: Studies in the epidemiology and preventability of rheumatic fever. IV. A quantitative determination of compliance in children on oral penicillin prophylaxis. Pediatrics 1969, 43:173-182.
• [28]Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J: Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. Med J Aust 2006, 184:514-517.
• [29]Mincham CM, Toussaint S, Mak DB, Plant AJ: Patient views on the management of rheumatic fever and rheumatic heart disease in the Kimberley: a qualitative study. Aust J Rural Health 2003, 11:260-265.
• [30]Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM: Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004, 19:638-645.
• [31]Briesacher BA, Gurwitz JH, Soumerai SB: Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 2007, 22:864-871.
• [32]Eaddy MT, Cook CL, O'Day K, Burch SP, Cantrell CR: How patient cost-sharing trends affect adherence and outcomes: a literature review. P T 2012, 37:45-55.
• [33]Gordis L, Markowitz M, Lilienfeld AM: Why patients don't follow medical advice: a study of children on long-term antistreptococcal prophylaxis. J Pediatr 1969, 75:957-968.